Journal
BIOMEDICINES
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10020283
Keywords
renal disease; RNA therapy; RNAi; miRNA; siRNA; nanoparticle; lipid nanocarrier
Categories
Funding
- National Taiwan University Hospital Yunlin Branch, Taiwan [NTUHYL 111.S022]
- National Taiwan University Cancer Centre [NTUCCS-111-02]
- Ministry of Science and Technology, Taiwan [MOST 109-2311-B-002-006-, MOST 108-2314-B-002-062-MY3]
Ask authors/readers for more resources
Kidney disease is a growing global burden, and the use of miRNAs and RNA therapy, which can be rapidly absorbed by kidneys, shows potential as an effective treatment option for renal diseases.
Kidney disease is a multifactorial problem, with a growing prevalence and an increasing global burden. With the latest worldwide data suggesting that chronic kidney disease (CKD) is the 12th leading cause of death, it is no surprise that CKD remains a public health problem that requires urgent attention. Multiple factors contribute to kidney disease, each with its own pathophysiology and pathogenesis. Furthermore, microRNAs (miRNAs) have been linked to several types of kidney diseases. As dysregulation of miRNAs is often seen in some diseases, there is potential in the exploitation of this for therapeutic applications. In addition, uptake of interference RNA has been shown to be rapid in kidneys making them a good candidate for RNA therapy. The latest advancements in RNA therapy and lipid-based nanocarriers have enhanced the effectiveness and efficiency of RNA-related drugs, thereby making RNA therapy a viable treatment option for renal disease. This is especially useful for renal diseases, for which a suitable treatment is not yet available. Moreover, the high adaptability of RNA therapy combined with the low risk of lipid-based nanocarriers make for an attractive treatment choice. Currently, there are only a small number of RNA-based drugs related to renal parenchymal disease, most of which are in different stages of clinical trials. We propose the use of miRNAs or short interfering RNAs coupled with a lipid-based nanocarrier as a delivery vehicle for managing renal disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available